메뉴 건너뛰기




Volumn 8, Issue 4, 2008, Pages 271-282

Controlled-release carvedilol

Author keywords

Adis Drug Evaluations; Alpha 1 adrenergic receptor antagonists, therapeutic use; Alpha beta adrenergic receptor antagonists, therapeutic use; Carvedilol, adverse reactions; Carvedilol, pharmacodynamics; Carvedilol, pharmacokinetics

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ATENOLOL; BETA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; CAPTOPRIL; CARVEDILOL; CIMETIDINE; COREG CR; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; GLIBENCLAMIDE; HYDROCHLOROTHIAZIDE; METOPROLOL; RIFAMPICIN; TORASEMIDE; WARFARIN;

EID: 49449085809     PISSN: 11753277     EISSN: None     Source Type: Journal    
DOI: 10.2165/00129784-200808040-00007     Document Type: Review
Times cited : (3)

References (79)
  • 1
    • 0038460302 scopus 로고    scopus 로고
    • The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report
    • May 21;
    • Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 Report. JAMA 2003 May 21; 289 (19): 2560-72
    • (2003) JAMA , Issue.19
    • Chobanian, A.V.1    Bakris, G.L.2    Black, H.R.3
  • 2
    • 49449084783 scopus 로고    scopus 로고
    • Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: summary article. Cirulation 2005 Sep 20; 112 (12): 1888-916
    • Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: summary article. Cirulation 2005 Sep 20; 112 (12): 1888-916
  • 3
    • 33749152764 scopus 로고    scopus 로고
    • COMPARE: Comparison of the effects of carvedilol CR and carvedilol IR on left ventricular ejection fraction in patients with heart failure
    • Oct 2;
    • Greenberg BH, Mehra M, Teerlink JR, et al. COMPARE: comparison of the effects of carvedilol CR and carvedilol IR on left ventricular ejection fraction in patients with heart failure. Am J Cardiol 2006 Oct 2; 98 Suppl. 1 (7): 53L-9L
    • (2006) Am J Cardiol , vol.98 , Issue.SUPPL. 1 7
    • Greenberg, B.H.1    Mehra, M.2    Teerlink, J.R.3
  • 4
    • 39049177405 scopus 로고    scopus 로고
    • Weber MA, Bakris GL, Tarka EA, et al. Efficacy of a once-daily formulation of carvedilol for the treatment of hypertension [published erratum appears in J Clin Hypertens 2007 Feb; 9 (2): 154]. J Clin Hypertens 2006 Dec; 8 (12): 840-9
    • Weber MA, Bakris GL, Tarka EA, et al. Efficacy of a once-daily formulation of carvedilol for the treatment of hypertension [published erratum appears in J Clin Hypertens 2007 Feb; 9 (2): 154]. J Clin Hypertens 2006 Dec; 8 (12): 840-9
  • 5
    • 33749118012 scopus 로고    scopus 로고
    • Rationale and design of CASPER: Compliance and quality of life study comparing once-daily carvedilol CR and twice-daily carvedilol IR in patients with heart failure
    • Oct 2;
    • Hauptman PJ, Pressler SJ, Sackner-Bernstein J, et al. Rationale and design of CASPER: compliance and quality of life study comparing once-daily carvedilol CR and twice-daily carvedilol IR in patients with heart failure. Am J Cardiol 2006 Oct 2; 98 (7 Suppl. 1): 60L-6L
    • (2006) Am J Cardiol , vol.98 , Issue.7 SUPPL. 1
    • Hauptman, P.J.1    Pressler, S.J.2    Sackner-Bernstein, J.3
  • 6
    • 49449113019 scopus 로고    scopus 로고
    • Coreg (carvedilol) tablets: US prescribing information. Research Triangle Park (NC): GlaxoSmithKline, 2007
    • Coreg (carvedilol) tablets: US prescribing information. Research Triangle Park (NC): GlaxoSmithKline, 2007
  • 7
    • 49449110338 scopus 로고    scopus 로고
    • GlaxoSmithKline. FDA approves new, once-a-day Coreg CR for the treatment of three key cardiovascular conditions [online]. Available from URL: http://www.gsk.com/ControllerServlet?appId=4&pageId=402&newsid=918 [Accessed 2008 Jan 3]
    • GlaxoSmithKline. FDA approves new, once-a-day Coreg CR for the treatment of three key cardiovascular conditions [online]. Available from URL: http://www.gsk.com/ControllerServlet?appId=4&pageId=402&newsid=918 [Accessed 2008 Jan 3]
  • 8
    • 49449105778 scopus 로고    scopus 로고
    • Coreg CR (carvedilol phosphate) extended-release capsules: US prescribing information. Research Triangle Park (NC): GlaxoSmithKline, 2007 Oct
    • Coreg CR (carvedilol phosphate) extended-release capsules: US prescribing information. Research Triangle Park (NC): GlaxoSmithKline, 2007 Oct
  • 9
    • 33749134422 scopus 로고    scopus 로고
    • Pharmacokinetic and pharmacodynamic comparison of controlled-release carvedilol and immediate-release carvedilol at steady state in patients with hypertension
    • Oct 2;
    • Henderson LS, Tenero DM, Baidoo CA, et al. Pharmacokinetic and pharmacodynamic comparison of controlled-release carvedilol and immediate-release carvedilol at steady state in patients with hypertension. Am J Cardiol 2006 Oct 2; 98 (7 Suppl. 1): 17L-26L
    • (2006) Am J Cardiol , vol.98 , Issue.7 SUPPL. 1
    • Henderson, L.S.1    Tenero, D.M.2    Baidoo, C.A.3
  • 10
    • 85047673757 scopus 로고
    • Acute haemodynamic effects of carvedilol (BM 14190), a new combined beta-adrenoceptor blocker and precapillary vasodilating agent, in hypertensive patients
    • Eggertsen R, Andren L, Sivertsson R, et al. Acute haemodynamic effects of carvedilol (BM 14190), a new combined beta-adrenoceptor blocker and precapillary vasodilating agent, in hypertensive patients. Eur J Clin Pharmacol 1984; 27 (1): 19-22
    • (1984) Eur J Clin Pharmacol , vol.27 , Issue.1 , pp. 19-22
    • Eggertsen, R.1    Andren, L.2    Sivertsson, R.3
  • 11
    • 0025863481 scopus 로고
    • Acute haemodynamic effects of carvedilol in essential hypertension at rest and during exercise
    • Sep;
    • Omvik P, Lund-Johansen P. Acute haemodynamic effects of carvedilol in essential hypertension at rest and during exercise. Eur Heart J 1991 Sep; 12 (6): 736-40
    • (1991) Eur Heart J , vol.12 , Issue.6 , pp. 736-740
    • Omvik, P.1    Lund-Johansen, P.2
  • 12
    • 0023638237 scopus 로고
    • Effect of carvedilol on ambulatory blood pressure, renal hemodynamics, and cardiac function in essential hypertension
    • Dupont AG, Van der Niepen P, Taeymans Y, et al. Effect of carvedilol on ambulatory blood pressure, renal hemodynamics, and cardiac function in essential hypertension. J Cardiovasc Pharmacol 1987; 10 Suppl. 11: S130-6
    • (1987) J Cardiovasc Pharmacol , vol.10 , Issue.SUPPL. 11
    • Dupont, A.G.1    Van der Niepen, P.2    Taeymans, Y.3
  • 13
    • 0026741197 scopus 로고
    • Hemodynamic effects of carvedilol after acute oral administration in hypertensive and normal subjects
    • Cournot A, Lim C, Duchier J, et al. Hemodynamic effects of carvedilol after acute oral administration in hypertensive and normal subjects. J Cardiovasc Pharmacol 1992; 19 Supp. 1: S35-9
    • (1992) J Cardiovasc Pharmacol , vol.19 , Issue.SUPP. 1
    • Cournot, A.1    Lim, C.2    Duchier, J.3
  • 14
    • 0021746176 scopus 로고
    • Haemodynamic effects of carvedilol, a new beta-adrenoceptor blocker and precapillary vasodilator in essential hypertension
    • Oct;
    • Eggertsen R, Sivertsson R, Andren L, et al. Haemodynamic effects of carvedilol, a new beta-adrenoceptor blocker and precapillary vasodilator in essential hypertension. J Hypertens 1984 Oct; 2 (5): 529-34
    • (1984) J Hypertens , vol.2 , Issue.5 , pp. 529-534
    • Eggertsen, R.1    Sivertsson, R.2    Andren, L.3
  • 15
    • 0023609539 scopus 로고
    • Acute and long-term hemodynamic effects of carvedilol, a combined β-adrenoceptor blocking and precapillary vasodilating agent, in hypertensive patients
    • Eggertsen R, Sivertsson R, Andrén L, et al. Acute and long-term hemodynamic effects of carvedilol, a combined β-adrenoceptor blocking and precapillary vasodilating agent, in hypertensive patients. J Cardiovasc Pharmacol 1987; 10 Suppl. 11: S97-S100
    • (1987) J Cardiovasc Pharmacol , vol.10 , Issue.SUPPL. 11
    • Eggertsen, R.1    Sivertsson, R.2    Andrén, L.3
  • 16
    • 0026573297 scopus 로고
    • Chronic haemodynamic effects of carvedilol in essential hypertension at rest and during exercise
    • Feb;
    • Lund-Johansen P, Omvik P. Chronic haemodynamic effects of carvedilol in essential hypertension at rest and during exercise. Eur Heart J 1992 Feb; 13 (2): 281-6
    • (1992) Eur Heart J , vol.13 , Issue.2 , pp. 281-286
    • Lund-Johansen, P.1    Omvik, P.2
  • 17
    • 0035131087 scopus 로고    scopus 로고
    • Dilated cardiomyopathy in dialysis patients: Beneficial effects of carvedilol. A double-blind, placebo-controlled trial
    • Cice G, Ferrara L, Di Benedetto A, et al. Dilated cardiomyopathy in dialysis patients: beneficial effects of carvedilol. A double-blind, placebo-controlled trial. J Am Coll Cardiol 2001; 37 (2): 407-11
    • (2001) J Am Coll Cardiol , vol.37 , Issue.2 , pp. 407-411
    • Cice, G.1    Ferrara, L.2    Di Benedetto, A.3
  • 18
    • 0033230514 scopus 로고    scopus 로고
    • Beta-blockade in heart failure: A comparison of carvedilol with metoprolol
    • Sanderson JE, Chan S, Yip G, et al. Beta-blockade in heart failure: a comparison of carvedilol with metoprolol. J Am Coll Cardiol 1999; 34 (5): 1522-8
    • (1999) J Am Coll Cardiol , vol.34 , Issue.5 , pp. 1522-1528
    • Sanderson, J.E.1    Chan, S.2    Yip, G.3
  • 19
    • 0032845314 scopus 로고    scopus 로고
    • Pulmonary function, cardiac function, and exercise capacity in a follow-up of patients with congestive heart failure treated with carvdilol
    • Sep;
    • Guazzi M, Agostoni P, Matturri M, et al. Pulmonary function, cardiac function, and exercise capacity in a follow-up of patients with congestive heart failure treated with carvdilol. Am Heart J 1999 Sep; 138 (3): 460-7
    • (1999) Am Heart J , vol.138 , Issue.3 , pp. 460-467
    • Guazzi, M.1    Agostoni, P.2    Matturri, M.3
  • 21
    • 0026772962 scopus 로고
    • Effect of carvedilol on left ventricular function and mass in hypertension
    • Why H, Richardson PJ. Effect of carvedilol on left ventricular function and mass in hypertension. J Cardiovasc Pharmacol 1992; 19 Suppl. 1: S50-4
    • (1992) J Cardiovasc Pharmacol , vol.19 , Issue.SUPPL. 1
    • Why, H.1    Richardson, P.J.2
  • 22
    • 0023624521 scopus 로고
    • Resting and postexercise hemodynamic effects of carvedilol, a β-adrenergic blocker and precapillary vasodilator in hypertensive patients
    • Leonetti G, Sampieri L, Cuspidi C, et al. Resting and postexercise hemodynamic effects of carvedilol, a β-adrenergic blocker and precapillary vasodilator in hypertensive patients. J Cardiovasc Pharmacol 1987; 10 Suppl. 11: S94-6
    • (1987) J Cardiovasc Pharmacol , vol.10 , Issue.SUPPL. 11
    • Leonetti, G.1    Sampieri, L.2    Cuspidi, C.3
  • 23
    • 0031050642 scopus 로고    scopus 로고
    • Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease
    • Australia/New Zealand Heart Failure Research Collaborative Group, Feb 8;
    • Australia/New Zealand Heart Failure Research Collaborative Group. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Lancet 1997 Feb 8; 349 (9049): 375-80
    • (1997) Lancet , vol.349 , Issue.9049 , pp. 375-380
  • 24
    • 0029085811 scopus 로고
    • Double-blind, placebo-controlled study of the long-term efficacy of carvdilol in patients with severe chronic heart failure
    • Sep 15;
    • Krum H, Sackner-Bernstein JD, Goldsmith RL, et al. Double-blind, placebo-controlled study of the long-term efficacy of carvdilol in patients with severe chronic heart failure. Circulation 1995 Sep 15; 92 (6): 1499-506
    • (1995) Circulation , vol.92 , Issue.6 , pp. 1499-1506
    • Krum, H.1    Sackner-Bernstein, J.D.2    Goldsmith, R.L.3
  • 25
    • 0028947523 scopus 로고
    • Carvedilol improves left ventricular function and symptoms in chronic heart failure: A double-blind randomised study
    • Olsen SL, Gilbert EM, Renlund DG, et al. Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomised study. J Am Coll Cardiol 1995; 25 (6): 1225-31
    • (1995) J Am Coll Cardiol , vol.25 , Issue.6 , pp. 1225-1231
    • Olsen, S.L.1    Gilbert, E.M.2    Renlund, D.G.3
  • 26
    • 10544223267 scopus 로고    scopus 로고
    • Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure
    • Dec 1;
    • Bristow MR, Gilbert EM, Abraham WT, et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation 1996 Dec 1; 94 (11): 2807-16
    • (1996) Circulation , vol.94 , Issue.11 , pp. 2807-2816
    • Bristow, M.R.1    Gilbert, E.M.2    Abraham, W.T.3
  • 27
    • 0031230455 scopus 로고    scopus 로고
    • Safety and efficacy of carvedilol in severe heart failure: The U.S. Carvedilol Heart Failure Study Group
    • Sep;
    • Cohn JN, Fowler MB, Bristow MR, et al. Safety and efficacy of carvedilol in severe heart failure: the U.S. Carvedilol Heart Failure Study Group. J Card Fail 1997 Sep; 3 (3): 173-9
    • (1997) J Card Fail , vol.3 , Issue.3 , pp. 173-179
    • Cohn, J.N.1    Fowler, M.B.2    Bristow, M.R.3
  • 28
    • 10544231452 scopus 로고    scopus 로고
    • Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure
    • Dec 1;
    • Colucci WS, Packer M, Bristow MR, et al. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. Circulation 1996 Dec 1; 94 (11): 2800-6
    • (1996) Circulation , vol.94 , Issue.11 , pp. 2800-2806
    • Colucci, W.S.1    Packer, M.2    Bristow, M.R.3
  • 29
    • 10544251442 scopus 로고    scopus 로고
    • Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure: The PRECISE trial
    • Dec 1;
    • Packer M, Colucci WS, Sackner-Bernstein JD, et al. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure: the PRECISE trial. Circulation 1996 Dec 1; 94 (11): 2793-9
    • (1996) Circulation , vol.94 , Issue.11 , pp. 2793-2799
    • Packer, M.1    Colucci, W.S.2    Sackner-Bernstein, J.D.3
  • 30
    • 0035370722 scopus 로고    scopus 로고
    • Comparative effects of carvedilol and metoprolol on left ventricular ejection fraction in heart failure: Results of a meta-analysis
    • Jun;
    • Packer M, Antonopoulos GV, Berlin JA, et al. Comparative effects of carvedilol and metoprolol on left ventricular ejection fraction in heart failure: results of a meta-analysis. Am Heart J 2001 Jun; 141 (6): 899-907
    • (2001) Am Heart J , vol.141 , Issue.6 , pp. 899-907
    • Packer, M.1    Antonopoulos, G.V.2    Berlin, J.A.3
  • 31
    • 1342284053 scopus 로고    scopus 로고
    • Effect of carvedilol on diastolic function in patients with diastolic heart failure and preserved systolic function. Results of the Swedish doppler-echocardiographic study (SWEDIC)
    • Jun;
    • Bergström A, Andersson B, Edner M, et al. Effect of carvedilol on diastolic function in patients with diastolic heart failure and preserved systolic function. Results of the Swedish doppler-echocardiographic study (SWEDIC). Eur J Heart Fail 2004 Jun; 6 (4): 453-61
    • (2004) Eur J Heart Fail , vol.6 , Issue.4 , pp. 453-461
    • Bergström, A.1    Andersson, B.2    Edner, M.3
  • 32
    • 0036895484 scopus 로고    scopus 로고
    • Effects of carvedilol on left ventricular remodeling and systolic function in elderly patients with heart failure
    • Dec;
    • Palazzuoli A, Bruni F, Puccetti L, et al. Effects of carvedilol on left ventricular remodeling and systolic function in elderly patients with heart failure. Eur J Heart Fail 2002 Dec; 4 (6): 765-70
    • (2002) Eur J Heart Fail , vol.4 , Issue.6 , pp. 765-770
    • Palazzuoli, A.1    Bruni, F.2    Puccetti, L.3
  • 33
    • 0032958134 scopus 로고    scopus 로고
    • Carvedilol prevents remodeling in patients with left ventricular dysfunction after acute myocardial infarction
    • Apr;
    • Senior R, Basu S, Kinsey C, et al. Carvedilol prevents remodeling in patients with left ventricular dysfunction after acute myocardial infarction. Am Heart J 1999 Apr; 137 (4): 646-52
    • (1999) Am Heart J , vol.137 , Issue.4 , pp. 646-652
    • Senior, R.1    Basu, S.2    Kinsey, C.3
  • 34
    • 1642494797 scopus 로고    scopus 로고
    • Effects of carvedilol on left ventricular remodeling after acute myocardial infarction: The CAPRICORN echo substudy
    • Jan 20;
    • Doughty RN, Whalley GA, Walsh HA, et al. Effects of carvedilol on left ventricular remodeling after acute myocardial infarction: the CAPRICORN echo substudy. Circulation 2004 Jan 20; 109 (2): 201-6
    • (2004) Circulation , vol.109 , Issue.2 , pp. 201-206
    • Doughty, R.N.1    Whalley, G.A.2    Walsh, H.A.3
  • 35
    • 0034255060 scopus 로고    scopus 로고
    • Differential effects of β-blockers in patients with heart failure: A prospective, randomized, double-blind comparison of the long-term effects of metoprolol versus carvedilol
    • Aug 1;
    • Metra M, Giubbini R, Nodari S, et al. Differential effects of β-blockers in patients with heart failure: a prospective, randomized, double-blind comparison of the long-term effects of metoprolol versus carvedilol. Circulation 2000 Aug 1; 102 (5): 546-51
    • (2000) Circulation , vol.102 , Issue.5 , pp. 546-551
    • Metra, M.1    Giubbini, R.2    Nodari, S.3
  • 36
    • 0034816963 scopus 로고    scopus 로고
    • Regression of left ventricular remodeling in chronic heart failure: Comparative and combined effects of captopril and carvedilol
    • Oct;
    • Khattar RS, Senior R, Soman P, et al. Regression of left ventricular remodeling in chronic heart failure: comparative and combined effects of captopril and carvedilol. Am Heart J 2001 Oct; 142 (4): 704-13
    • (2001) Am Heart J , vol.142 , Issue.4 , pp. 704-713
    • Khattar, R.S.1    Senior, R.2    Soman, P.3
  • 37
    • 3342943389 scopus 로고    scopus 로고
    • The benefits of early combination treatment of carvedilol and an ACE-inhibitor in mild heart failure and left ventricular systolic dysfunction: The carvedilol and ACE-inhibitor remodelling mild heart failure evaluation trial (CARMEN)
    • Jan;
    • Remme W, Guenter R, Hildebrandt P, et al. The benefits of early combination treatment of carvedilol and an ACE-inhibitor in mild heart failure and left ventricular systolic dysfunction: the carvedilol and ACE-inhibitor remodelling mild heart failure evaluation trial (CARMEN). Cardiovasc Drugs Ther 2004 Jan; 18 (1): 57-66
    • (2004) Cardiovasc Drugs Ther , vol.18 , Issue.1 , pp. 57-66
    • Remme, W.1    Guenter, R.2    Hildebrandt, P.3
  • 39
    • 0033662177 scopus 로고    scopus 로고
    • Congestive heart failure induces endothelial cell apoptosis: Protective role of carvedilol
    • Rössig L, Haendeler J, Mallat Z, et al. Congestive heart failure induces endothelial cell apoptosis: protective role of carvedilol. J Am Coll Cardiol 2000; 36 (7): 2081-9
    • (2000) J Am Coll Cardiol , vol.36 , Issue.7 , pp. 2081-2089
    • Rössig, L.1    Haendeler, J.2    Mallat, Z.3
  • 40
    • 0033979444 scopus 로고    scopus 로고
    • Carvedilol prevents epinephrine-induced apoptosis in human coronary artery endothelial cells: Modulation of Fas/Fas ligand and caspase-3 pathway
    • Romeo F, Li D, Shi M, et al. Carvedilol prevents epinephrine-induced apoptosis in human coronary artery endothelial cells: modulation of Fas/Fas ligand and caspase-3 pathway. Cardiovasc Res 2000; 45: 788-94
    • (2000) Cardiovasc Res , vol.45 , pp. 788-794
    • Romeo, F.1    Li, D.2    Shi, M.3
  • 41
    • 0032498614 scopus 로고    scopus 로고
    • Possible involvement of stress-activated protein kinase signaling pathway and Fas receptor expression in prevention of ischemia/reperfusion-induced cardiomyocyte apoptosis by carvedilol
    • Yue T-L, Ma X-L, Wang X, et al. Possible involvement of stress-activated protein kinase signaling pathway and Fas receptor expression in prevention of ischemia/reperfusion-induced cardiomyocyte apoptosis by carvedilol. Circ Res 1998; 82: 166-74
    • (1998) Circ Res , vol.82 , pp. 166-174
    • Yue, T.-L.1    Ma, X.-L.2    Wang, X.3
  • 42
    • 0028934620 scopus 로고
    • Inhibition of human vascular smooth muscle cell proliferation by the novel multiple-action antihypertensive agent carvedilol
    • Patel MK, Chan P, Betteridge LJ, et al. Inhibition of human vascular smooth muscle cell proliferation by the novel multiple-action antihypertensive agent carvedilol. J Cardiovasc Pharmacol 1995; 25 (4): 652-7
    • (1995) J Cardiovasc Pharmacol , vol.25 , Issue.4 , pp. 652-657
    • Patel, M.K.1    Chan, P.2    Betteridge, L.J.3
  • 43
    • 0027529916 scopus 로고
    • Carvedilol inhibits vascular smooth muscle cell proliferation
    • Sung C-P, Arleth AJ, Ohlstein EH, et al. Carvedilol inhibits vascular smooth muscle cell proliferation. J Cardiovasc Pharmacol 1993; 21 (2): 221-7
    • (1993) J Cardiovasc Pharmacol , vol.21 , Issue.2 , pp. 221-227
    • Sung, C.-P.1    Arleth, A.J.2    Ohlstein, E.H.3
  • 44
    • 0027163945 scopus 로고
    • Carvedilol, a cardiovascular drug, prevents vascular smooth muscle cell proliferation, migration, and neointimal formation following vascular injury
    • Jul;
    • Ohlstein EH, Douglas SA, Sung CP, et al. Carvedilol, a cardiovascular drug, prevents vascular smooth muscle cell proliferation, migration, and neointimal formation following vascular injury. Proc Natl Acad Sci U S A 1993 Jul; 90: 6189-93
    • (1993) Proc Natl Acad Sci U S A , vol.90 , pp. 6189-6193
    • Ohlstein, E.H.1    Douglas, S.A.2    Sung, C.P.3
  • 45
    • 0028032255 scopus 로고
    • Acute pretreatment with carvedilol is sufficient for inhibition of neointima formation following rat carotid artery balloon angioplasty
    • Douglas SA, Vickery-Clark LM, Louden C, et al. Acute pretreatment with carvedilol is sufficient for inhibition of neointima formation following rat carotid artery balloon angioplasty. Pharmacol Commun 1994; 5 (1): 65-72
    • (1994) Pharmacol Commun , vol.5 , Issue.1 , pp. 65-72
    • Douglas, S.A.1    Vickery-Clark, L.M.2    Louden, C.3
  • 46
    • 20944438124 scopus 로고    scopus 로고
    • Carvedilol therapy is associated with a sustained decline in brain natriuretic peptide levels in patients with congestive heart failure
    • Mar;
    • Frantz RP, Olson LJ, Grill D, et al. Carvedilol therapy is associated with a sustained decline in brain natriuretic peptide levels in patients with congestive heart failure. Am Heart J 2005 Mar; 149 (3): 541-7
    • (2005) Am Heart J , vol.149 , Issue.3 , pp. 541-547
    • Frantz, R.P.1    Olson, L.J.2    Grill, D.3
  • 47
    • 4344586997 scopus 로고    scopus 로고
    • Effects of carvedilol on plasma B-type natriuretic peptide concentration and symptoms in patients with heart failure and preserved ejection fraction
    • Aug 15;
    • Takeda Y, Fukutomi T, Suzuki S, et al. Effects of carvedilol on plasma B-type natriuretic peptide concentration and symptoms in patients with heart failure and preserved ejection fraction. Am J Cardiol 2004 Aug 15; 94 (4): 448-53
    • (2004) Am J Cardiol , vol.94 , Issue.4 , pp. 448-453
    • Takeda, Y.1    Fukutomi, T.2    Suzuki, S.3
  • 48
    • 34250638587 scopus 로고    scopus 로고
    • Effects of carvedilol versus metoprolol on endothelial function and oxidative stress in patients with type 2 diabetes mellitus
    • Jul;
    • Bank AJ, Kelly AS, Thelen AM, et al. Effects of carvedilol versus metoprolol on endothelial function and oxidative stress in patients with type 2 diabetes mellitus. Am J Hypertens 2007 Jul; 20 (7): 777-83
    • (2007) Am J Hypertens , vol.20 , Issue.7 , pp. 777-783
    • Bank, A.J.1    Kelly, A.S.2    Thelen, A.M.3
  • 49
    • 0034828069 scopus 로고    scopus 로고
    • Carvedilol increases plasma vascular endothelial growth factor (VEGF) in patients with chronic heart failure
    • de Boer RA, Siebelink H-M, Tio RA, et al. Carvedilol increases plasma vascular endothelial growth factor (VEGF) in patients with chronic heart failure. Eur J Heart Fail 2001; 3: 331-3
    • (2001) Eur J Heart Fail , vol.3 , pp. 331-333
    • de Boer, R.A.1    Siebelink, H.-M.2    Tio, R.A.3
  • 50
    • 49449115419 scopus 로고    scopus 로고
    • New aspects of endothelial dysfunction in heart failure [abstract no. 1993]
    • Aug;
    • Refsgaard J, Andreasen F, Goetzsche O, et al. New aspects of endothelial dysfunction in heart failure [abstract no. 1993]. Eur Heart J 1999 Aug; 20 Suppl.: 375
    • (1999) Eur Heart J , vol.20 , Issue.SUPPL. 375
    • Refsgaard, J.1    Andreasen, F.2    Goetzsche, O.3
  • 51
    • 0030943599 scopus 로고    scopus 로고
    • Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension
    • Jun 15;
    • Giugliano D, Acampora R, Marfella R, et al. Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. Ann Intern Med 1997 Jun 15; 126 (12): 955-9
    • (1997) Ann Intern Med , vol.126 , Issue.12 , pp. 955-959
    • Giugliano, D.1    Acampora, R.2    Marfella, R.3
  • 53
    • 7744237066 scopus 로고    scopus 로고
    • Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: A randomized controlled trial
    • Nov 10;
    • Bakris GL, Fonseca V, Katholi RE, et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA 2004 Nov 10; 292 (18): 2227-36
    • (2004) JAMA , vol.292 , Issue.18 , pp. 2227-2236
    • Bakris, G.L.1    Fonseca, V.2    Katholi, R.E.3
  • 54
    • 0025371556 scopus 로고
    • Effects of carvedilol on renal function
    • Dupont AG. Effects of carvedilol on renal function. Eur J Clin Pharmacol 1990; 38 Suppl. 2: S96-S100
    • (1990) Eur J Clin Pharmacol , vol.38 , Issue.SUPPL. 2
    • Dupont, A.G.1
  • 55
    • 0001472278 scopus 로고    scopus 로고
    • Carvedilol improves renal hemodynamics in patients with chronic heart failure [abstract no. 1987]
    • Oct 27;
    • Abraham WT, Tsvetkova T, Lowes BD, et al. Carvedilol improves renal hemodynamics in patients with chronic heart failure [abstract no. 1987]. Circulation 1998 Oct 27; 98 Suppl.: I378-9
    • (1998) Circulation , vol.98 , Issue.SUPPL.
    • Abraham, W.T.1    Tsvetkova, T.2    Lowes, B.D.3
  • 56
    • 0029074823 scopus 로고
    • Efficacy of carvedilol in mild to moderate essential hypertension and effects on microalbuminuria: A multicenter, randomized, open-label, controlled study versus atenolol
    • Marchi F, Ciriello G. Efficacy of carvedilol in mild to moderate essential hypertension and effects on microalbuminuria: a multicenter, randomized, open-label, controlled study versus atenolol. Adv Ther 1995; 12 (4): 212-21
    • (1995) Adv Ther , vol.12 , Issue.4 , pp. 212-221
    • Marchi, F.1    Ciriello, G.2
  • 57
    • 0029969823 scopus 로고    scopus 로고
    • Effect of antihypertensive treatment on qualitative estimates of microalbuminuria
    • Agrawal B, Wolf K, Berger A, et al. Effect of antihypertensive treatment on qualitative estimates of microalbuminuria. J Hum Hypertens 1996; 10: 551-5
    • (1996) J Hum Hypertens , vol.10 , pp. 551-555
    • Agrawal, B.1    Wolf, K.2    Berger, A.3
  • 58
    • 2942618618 scopus 로고    scopus 로고
    • Tolerability of carvedilol and ACE-inhibition in mild heart failure: Results of CARMEN (carvedilol ACE-inhibitor remodelling mild CHF evaluation)
    • Komajda M, Lutiger B, Madeira H, et al. Tolerability of carvedilol and ACE-inhibition in mild heart failure: results of CARMEN (carvedilol ACE-inhibitor remodelling mild CHF evaluation). Eur Heart J 2004; 6: 467-75
    • (2004) Eur Heart J , vol.6 , pp. 467-475
    • Komajda, M.1    Lutiger, B.2    Madeira, H.3
  • 59
    • 30444451911 scopus 로고    scopus 로고
    • Differential effects of beta-blockers on albuminuria in patients with type 2 diabetes
    • Dec;
    • Bakris GL, Fonseca V, Katholi RE, et al. Differential effects of beta-blockers on albuminuria in patients with type 2 diabetes. Hypertension 2005 Dec; 46 (6): 1309-15
    • (2005) Hypertension , vol.46 , Issue.6 , pp. 1309-1315
    • Bakris, G.L.1    Fonseca, V.2    Katholi, R.E.3
  • 60
    • 0029035966 scopus 로고
    • Stereoselective disposition of carvedilol is determined by CYP2D6
    • May;
    • Zhou H-H WA. Stereoselective disposition of carvedilol is determined by CYP2D6. Clin Pharmacol Ther 1995 May; 57 (5): 518-24
    • (1995) Clin Pharmacol Ther , vol.57 , Issue.5 , pp. 518-524
    • Zhou, H.-H.W.1
  • 61
    • 0042233484 scopus 로고    scopus 로고
    • Carvedilol: A review of its use in chronic heart failure
    • Keating GM, Jarvis B. Carvedilol: a review of its use in chronic heart failure. Drugs 2003; 63 (16): 1697-741
    • (2003) Drugs , vol.63 , Issue.16 , pp. 1697-1741
    • Keating, G.M.1    Jarvis, B.2
  • 62
    • 0027506396 scopus 로고
    • Carvedilol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy
    • McTavish D, Campoli-Richards D, Sorkin EM. Carvedilol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs 1993; 45 (2): 232-58
    • (1993) Drugs , vol.45 , Issue.2 , pp. 232-258
    • McTavish, D.1    Campoli-Richards, D.2    Sorkin, E.M.3
  • 63
    • 0030843847 scopus 로고    scopus 로고
    • Carvedilol. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders
    • Dunn CJ, Lea AP, Wagstaff AJ. Carvedilol. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders. Drugs 1997; 54 (1): 161-85
    • (1997) Drugs , vol.54 , Issue.1 , pp. 161-185
    • Dunn, C.J.1    Lea, A.P.2    Wagstaff, A.J.3
  • 64
    • 33947111435 scopus 로고    scopus 로고
    • Antioxidant activity of carvedilol in cardiovascular disease
    • Apr;
    • Dandona P, Ghanim H, Brooks DP. Antioxidant activity of carvedilol in cardiovascular disease. J Hypertens 2007 Apr; 25 (4): 731-41
    • (2007) J Hypertens , vol.25 , Issue.4 , pp. 731-741
    • Dandona, P.1    Ghanim, H.2    Brooks, D.P.3
  • 65
    • 33845574557 scopus 로고    scopus 로고
    • Profile of carvedilol controlled-release: A new once-daily formulation of carvedilol
    • Dec;
    • Fonarow GC. Profile of carvedilol controlled-release: a new once-daily formulation of carvedilol. Expert Opin Pharmacother 2006 Dec; 7 (18): 2533-46
    • (2006) Expert Opin Pharmacother , vol.7 , Issue.18 , pp. 2533-2546
    • Fonarow, G.C.1
  • 66
    • 33845394025 scopus 로고    scopus 로고
    • Carreira RS, Monteiro P, Gonçalves LM, et al. Carvedilol: just another beta-blocker or a powerful cardioprotector? Cardiovasc Hematol Disord Drug Targets 2006 Dec; 6 (4): 257-66
    • Carreira RS, Monteiro P, Gonçalves LM, et al. Carvedilol: just another beta-blocker or a powerful cardioprotector? Cardiovasc Hematol Disord Drug Targets 2006 Dec; 6 (4): 257-66
  • 67
    • 8444235096 scopus 로고    scopus 로고
    • Carvedilol but not metoprolol reduces β-adrenergic responsiveness after complete elimination from plasma in vivo
    • Jun 29;
    • Kindermann M, Maack C, Schaller S, et al. Carvedilol but not metoprolol reduces β-adrenergic responsiveness after complete elimination from plasma in vivo. Circulation 2004 Jun 29; 109 (25): 3182-90
    • (2004) Circulation , vol.109 , Issue.25 , pp. 3182-3190
    • Kindermann, M.1    Maack, C.2    Schaller, S.3
  • 68
    • 33749118663 scopus 로고    scopus 로고
    • Pharmacokinetic profile of controlled-release carvedilol in patients with left ventricular dysfunction associated with chronic heart failure or after myocardial infarction
    • Oct 2;
    • Packer M, Lukas MA, Tenero DM, et al. Pharmacokinetic profile of controlled-release carvedilol in patients with left ventricular dysfunction associated with chronic heart failure or after myocardial infarction. Am J Cardiol 2006 Oct 2; 98 (7 Suppl. 1): 39L-45L
    • (2006) Am J Cardiol , vol.98 , Issue.7 SUPPL. 1
    • Packer, M.1    Lukas, M.A.2    Tenero, D.M.3
  • 69
    • 33749129554 scopus 로고    scopus 로고
    • Pharmacokinetic properties of a new controlled-release formulation of carvedilol
    • Oct 2;
    • Tenero DM, Henderson LS, Baidoo CA, et al. Pharmacokinetic properties of a new controlled-release formulation of carvedilol. Am J Cardiol 2006 Oct 2; 98 (7 Suppl. 1): 5L-16L
    • (2006) Am J Cardiol , vol.98 , Issue.7 SUPPL. 1
    • Tenero, D.M.1    Henderson, L.S.2    Baidoo, C.A.3
  • 70
    • 0023612138 scopus 로고
    • Pharmacokinetics and disposition of carvedilol in humans
    • Neugebauer G, Akpan W, Möllendorff EV, et al. Pharmacokinetics and disposition of carvedilol in humans. J Cardiovasc Pharmacol 1987; 10 Suppl. 11: S85-8
    • (1987) J Cardiovasc Pharmacol , vol.10 , Issue.SUPPL. 11
    • Neugebauer, G.1    Akpan, W.2    Möllendorff, E.V.3
  • 71
    • 49449095950 scopus 로고    scopus 로고
    • Data on file. GlaxoSmithKline, 2008
    • Data on file. GlaxoSmithKline, 2008
  • 72
    • 0032957957 scopus 로고    scopus 로고
    • The pharmacokinetics of carvedilol and its metabolites after single and multiple dose oral administration in patients with hypertension and renal insufficiency
    • Jun;
    • Gehr T, Tenero DM, Boyle DA, et al. The pharmacokinetics of carvedilol and its metabolites after single and multiple dose oral administration in patients with hypertension and renal insufficiency. Eur J Clin Pharmacol 1999 Jun; 55 (4): 269-77
    • (1999) Eur J Clin Pharmacol , vol.55 , Issue.4 , pp. 269-277
    • Gehr, T.1    Tenero, D.M.2    Boyle, D.A.3
  • 73
    • 35448958493 scopus 로고    scopus 로고
    • Ethanol does not alter the pharmacokinetic profile of the controlled-release formulation of carvedilol
    • Nov;
    • Henderson LS, Tenero DM, Campanile AM, et al. Ethanol does not alter the pharmacokinetic profile of the controlled-release formulation of carvedilol. J Clin Pharmacol 2007 Nov; 47 (11): 1358-65
    • (2007) J Clin Pharmacol , vol.47 , Issue.11 , pp. 1358-1365
    • Henderson, L.S.1    Tenero, D.M.2    Campanile, A.M.3
  • 74
    • 0035978763 scopus 로고    scopus 로고
    • Effect of carvedilol on survival in severe chronic heart failure
    • May 31;
    • Packer M, Coats A, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001 May 31; 344 (22): 1651-8
    • (2001) N Engl J Med , vol.344 , Issue.22 , pp. 1651-1658
    • Packer, M.1    Coats, A.2    Fowler, M.B.3
  • 75
    • 3142776467 scopus 로고    scopus 로고
    • Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): Randomised controlled trial
    • Jul 5;
    • Poole-Wilson PA, Swedberg K, Cleland JGF, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 2003 Jul 5; 362 (9377): 7-13
    • (2003) Lancet , vol.362 , Issue.9377 , pp. 7-13
    • Poole-Wilson, P.A.1    Swedberg, K.2    Cleland, J.G.F.3
  • 76
    • 33749126575 scopus 로고    scopus 로고
    • Controlled-release carvedilol in the treatment of essential hypertension
    • Oct 2;
    • Weber MA, Sica DA, Tarka EA, et al. Controlled-release carvedilol in the treatment of essential hypertension. Am J Cardiol 2006 Oct 2; 98 (7 Suppl. 1): 32L-8L
    • (2006) Am J Cardiol , vol.98 , Issue.7 SUPPL. 1
    • Weber, M.A.1    Sica, D.A.2    Tarka, E.A.3
  • 77
    • 33749340025 scopus 로고    scopus 로고
    • Cardiovascular risk factors in hypertension: Rationale and design of studies to investigate the effects of controlled-release carvedilol on regression of left ventricular hypertrophy and lipid profile
    • Oct 2;
    • Bakris GL, Tarka EA, Waterhouse B, et al. Cardiovascular risk factors in hypertension: rationale and design of studies to investigate the effects of controlled-release carvedilol on regression of left ventricular hypertrophy and lipid profile. Am J Cardiol 2006 Oct 2; 98 (7 Suppl. 1): 46L-52L
    • (2006) Am J Cardiol , vol.98 , Issue.7 SUPPL. 1
    • Bakris, G.L.1    Tarka, E.A.2    Waterhouse, B.3
  • 78
    • 49449088869 scopus 로고    scopus 로고
    • Compliance with once daily controlled release vs twice daily immediate release carvedilol in patients with heart failure: The CASPER trial
    • Aug;
    • Udelson JE, Pressler SJ, Sackner-Bernstein J, et al. Compliance with once daily controlled release vs twice daily immediate release carvedilol in patients with heart failure: the CASPER trial. J Card Fail 2007 Aug; 13 (6 Suppl. S2): S135
    • (2007) J Card Fail , vol.13 , Issue.6 SUPPL. S2
    • Udelson, J.E.1    Pressler, S.J.2    Sackner-Bernstein, J.3
  • 79
    • 0035810547 scopus 로고    scopus 로고
    • Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: The CAPRICORN randomised trial
    • The CAPRICORN Investigators, May 5;
    • The CAPRICORN Investigators. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 2001 May 5; 357 (9266): 1385-90
    • (2001) Lancet , vol.357 , Issue.9266 , pp. 1385-1390


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.